Switch theme
Sign up to access all valuation multiples
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
2020
155
LTM Revenue $36.5M
Last FY EBITDA -$143M
$59.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Tango Therapeutics has a last 12-month revenue (LTM) of $36.5M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Tango Therapeutics achieved revenue of $42.1M and an EBITDA of -$143M.
Tango Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Tango Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $36.5M | XXX | $42.1M | XXX | XXX | XXX |
| Gross Profit | $36.5M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$143M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -340% | XXX | XXX | XXX |
| EBIT | -$154M | XXX | -$146M | XXX | XXX | XXX |
| EBIT Margin | -421% | XXX | -346% | XXX | XXX | XXX |
| Net Profit | -$140M | XXX | -$130M | XXX | XXX | XXX |
| Net Margin | -384% | XXX | -310% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Tango Therapeutics's stock price is $2.
Tango Therapeutics has current market cap of $240M, and EV of $59.8M.
See Tango Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $59.8M | $240M | XXX | XXX | XXX | XXX | $-1.26 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Tango Therapeutics has market cap of $240M and EV of $59.8M.
Tango Therapeutics's trades at 1.4x EV/Revenue multiple, and -0.4x EV/EBITDA.
Equity research analysts estimate Tango Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Tango Therapeutics has a P/E ratio of -1.7x.
See valuation multiples for Tango Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $240M | XXX | $240M | XXX | XXX | XXX |
| EV (current) | $59.8M | XXX | $59.8M | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.4x | XXX | XXX | XXX |
| EV/EBIT | -0.4x | XXX | -0.4x | XXX | XXX | XXX |
| EV/Gross Profit | 1.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.7x | XXX | -1.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTango Therapeutics's last 12 month revenue growth is -21%
Tango Therapeutics's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $1.2M for the same period.
Tango Therapeutics's rule of 40 is -327% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Tango Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Tango Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -21% | XXX | -17% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -340% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -327% | XXX | -361% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 342% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 446% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Tango Therapeutics acquired XXX companies to date.
Last acquisition by Tango Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Tango Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Tango Therapeutics founded? | Tango Therapeutics was founded in 2020. |
| Where is Tango Therapeutics headquartered? | Tango Therapeutics is headquartered in United States of America. |
| How many employees does Tango Therapeutics have? | As of today, Tango Therapeutics has 155 employees. |
| Who is the CEO of Tango Therapeutics? | Tango Therapeutics's CEO is Dr. Barbara L. Weber, M.D.. |
| Is Tango Therapeutics publicy listed? | Yes, Tango Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Tango Therapeutics? | Tango Therapeutics trades under TNGX ticker. |
| When did Tango Therapeutics go public? | Tango Therapeutics went public in 2021. |
| Who are competitors of Tango Therapeutics? | Similar companies to Tango Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Tango Therapeutics? | Tango Therapeutics's current market cap is $240M |
| What is the current revenue of Tango Therapeutics? | Tango Therapeutics's last 12 months revenue is $36.5M. |
| What is the current revenue growth of Tango Therapeutics? | Tango Therapeutics revenue growth (NTM/LTM) is -21%. |
| What is the current EV/Revenue multiple of Tango Therapeutics? | Current revenue multiple of Tango Therapeutics is 1.6x. |
| Is Tango Therapeutics profitable? | Yes, Tango Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
